Global efforts to stop the spread of the Coronavirus, or COVID-19, have been stepped up in recent days, with the combined situation in South Korea, Italy and Iran as well as the tens of thousands of people infected in China, causing UK broadcaster the BBC to call the outbreak “the early stages of pandemic”.
The effects across the world are already varied – from restrictions on the movement of people in certain geographies, to the closure of factories in China affecting supply chains across industries – and on Monday, financial markets were dented as investors wondered if the virus’ impact might be worse than previously feared.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze